Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12625000051448p
Ethics application status
Not yet submitted
Date submitted
18/12/2024
Date registered
20/01/2025
Date last updated
20/01/2025
Date data sharing statement initially provided
20/01/2025
Type of registration
Prospectively registered
Titles & IDs
Public title
Does corticosteroids help with non-malignant small bowel obstructions: A Study on Outcomes and Safety
Query!
Scientific title
A Prospective Observational Study Evaluating the Use of Corticosteroids in Adults with Non-Malignant Small Bowel Obstruction and Their Association with Resolution Without Surgical Intervention
Query!
Secondary ID [1]
313549
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Small bowel obstruction
336123
0
Query!
Condition category
Condition code
Surgery
332674
332674
0
0
Query!
Other surgery
Query!
Oral and Gastrointestinal
332673
332673
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Intervention:
Drug Name: Dexamethasone (International Non-Proprietary Name)
Dose: 4mg administered intravenously, twice daily
Duration: Up to 5 days or until clinical resolution of small bowel obstruction or clinical indication for surgery, whichever occurs first
Mode of Administration: Intravenous injection in an inpatient hospital setting
Who Delivers the Intervention: Experienced surgeons familiar with corticosteroid use for SBO management
Observation and Monitoring: Daily clinical evaluations and imaging (as needed) to monitor for SBO resolution, regimen adherence, and adverse events. Observations and follow up continue up to 90 days post-resolution or surgery to capture long-term outcomes.
Query!
Intervention code [1]
330187
0
Treatment: Drugs
Query!
Comparator / control treatment
Arm 1 (Control): No corticosteroids. Standard non-operative management, including nasogastric decompression, nil by mouth (NPO), and fluid resuscitation.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
340200
0
Proportion of patients with resolution of non-malignant small bowel obstruction (SBO) without the need for surgical intervention.
Query!
Assessment method [1]
340200
0
Composite primary outcome Resolution of SBO assessed as a composite outcome based on the following criteria: Resolution of abdominal pain and distension: Measured using daily clinical evaluations using the Numerical Rating Scale (NRS) for pain or the Visual Analogue Scale (VAS) for pain if the patient is unable to verbalise. Additionally, abdominal examination will evaluate both pain and distention by inspection for visible distention, palpation for tenderness and rigidity and percussion for tympany. Return of bowel function: Assessed by documentation of passage of flatus or stool, recorded in patient clinical notes. Imaging findings demonstrating resolution: Assessed by follow-up abdominal X-ray or CT scan (if clinically indicated).
Query!
Timepoint [1]
340200
0
Assessment will occur at the point of clinical resolution or decision for surgical intervention, typically within 5 days from the start of treatment or hospital admission. Additional follow up will occur until discharge to confirm the outcome. Follow up 90 days post discharge to record if re-obstruction occurs.
Query!
Secondary outcome [1]
443249
0
Need for Surgical Intervention
Query!
Assessment method [1]
443249
0
Proportion of patients who require surgical intervention after initiation of conservative management.
Query!
Timepoint [1]
443249
0
At the conclusion of the intervention period (up to 5 days) and prior to discharge.
Query!
Secondary outcome [2]
443247
0
Safety of corticosteroids
Query!
Assessment method [2]
443247
0
Incidence of known corticosteroid-related adverse events, including hyperglycemia (measured via blood glucose levels), infection (evidence from clinical signs or microbiological culture), and gastrointestinal bleeding (identified by clinical symptoms or endoscopic findings).
Query!
Timepoint [2]
443247
0
Monitored daily during hospitalisation and within 90 days post-discharge.
Query!
Secondary outcome [3]
443248
0
Time to Resolution of Small Bowel Obstruction
Query!
Assessment method [3]
443248
0
Number of days from initiation of treatment to documented clinical resolution of small bowel obstruction
Query!
Timepoint [3]
443248
0
Assessed daily during hospitalisation.
Query!
Secondary outcome [4]
443250
0
Length of Hospital Stay
Query!
Assessment method [4]
443250
0
Number of days from hospital admission to discharge.
Query!
Timepoint [4]
443250
0
Recorded at the time of discharge.
Query!
Eligibility
Key inclusion criteria
1. Diagnosis of Small Bowel Obstruction (SBO):
Confirmed adhesional small bowel obstruction based on clinical presentation and imaging (e.g., CT scan showing dilated loops of small bowel with transition point and no evidence of hernia or malignancy).
2. Age:
Adults aged 18 years and older.
3. Clinical Stability:
Hemodynamically stable and suitable for initial non-operative management.
4. Ability to Provide Informed Consent:
Patients capable of understanding the study protocol and providing written informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
85
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Malignant Obstruction:
Small bowel obstruction secondary to intra-abdominal or metastatic malignancy.
2. Hernia-Related Obstruction:
Patients with SBO caused by incarcerated or strangulated hernias identified clinically or radiologically.
3. Non-Adhesional Etiologies:
SBO caused by other specific etiologies such as inflammatory bowel disease, volvulus, or intussusception.
4. Immediate Surgical Indication:
Patients requiring urgent or emergent surgical intervention at the time of presentation.
5. Severe Comorbidities or Contraindications to Corticosteroids:
Active infections, poorly controlled diabetes, gastrointestinal ulcers, or other conditions contraindicating corticosteroid use.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Sample Size Calculation:
The required sample size of 200 participants was calculated to provide adequate power to detect a clinically significant difference in the resolution rate of non-malignant small bowel obstruction (SBO) without surgery between the corticosteroid and non-corticosteroid groups.
Assumptions for Calculation:
Expected resolution rate in the control group (no corticosteroids): 60%.
Expected resolution rate in the intervention group (corticosteroids): 80%.
Type I error rate (a): 5%.
Type II error rate (ß): 20% (power = 80%).
Two-sided test for differences in proportions between the two groups.
The sample size includes a margin for potential dropouts or exclusions during the study period.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/03/2025
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
1/03/2026
Query!
Actual
Query!
Date of last data collection
Anticipated
6/06/2026
Query!
Actual
Query!
Sample size
Target
200
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
27433
0
Liverpool Hospital - Liverpool
Query!
Recruitment postcode(s) [1]
43545
0
2170 - Liverpool
Query!
Funding & Sponsors
Funding source category [1]
318011
0
Self funded/Unfunded
Query!
Name [1]
318011
0
Query!
Address [1]
318011
0
Query!
Country [1]
318011
0
Query!
Primary sponsor type
Hospital
Query!
Name
Liverpool Hospital
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
320353
0
Hospital
Query!
Name [1]
320353
0
Campbelltown Hospital
Query!
Address [1]
320353
0
Query!
Country [1]
320353
0
Australia
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
316671
0
South Western Sydney Local Health District Human Research Ethics Committee
Query!
Ethics committee address [1]
316671
0
https://www.swslhd.health.nsw.gov.au/ethics/
Query!
Ethics committee country [1]
316671
0
Australia
Query!
Date submitted for ethics approval [1]
316671
0
30/01/2025
Query!
Approval date [1]
316671
0
Query!
Ethics approval number [1]
316671
0
Query!
Summary
Brief summary
This study aims to investigate whether corticosteroids can help resolve non-malignant small bowel obstruction caused by adhesions without the need for surgery. Small bowel obstruction is a common condition after abdominal surgery and is usually managed with treatments such as a nasogastric tube and fasting. Corticosteroids have anti-inflammatory properties that may reduce bowel swelling. Their use have been effective and safe in the setting of malignant bowel obstruction, but yet to be shown in non-malignant obstructions. We hypothesize that adding corticosteroids to standard non-surgical management will increase the likelihood of resolving the obstruction without surgery and improve recovery time. The study will also assess any potential side effects of corticosteroids.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
138606
0
Dr Ernest Cheng
Query!
Address
138606
0
Department of Colorectal Surgery, Liverpool Hospital, Burnside drive, Liverpool 2170
Query!
Country
138606
0
Australia
Query!
Phone
138606
0
+61 405002705
Query!
Fax
138606
0
Query!
Email
138606
0
[email protected]
Query!
Contact person for public queries
Name
138607
0
Ernest Cheng
Query!
Address
138607
0
Department of Colorectal Surgery, Liverpool Hospital, Burnside drive, Liverpool 2170
Query!
Country
138607
0
Australia
Query!
Phone
138607
0
+61 405002705
Query!
Fax
138607
0
Query!
Email
138607
0
[email protected]
Query!
Contact person for scientific queries
Name
138608
0
Ernest Cheng
Query!
Address
138608
0
Department of Colorectal Surgery, Liverpool Hospital, Burnside drive, Liverpool 2170
Query!
Country
138608
0
Australia
Query!
Phone
138608
0
+61 405002705
Query!
Fax
138608
0
Query!
Email
138608
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment:
While the study results and aggregated data will be shared through publications in peer-reviewed journals and presentations at scientific conferences, individual participant data (IPD) will not be made publicly available due to privacy concerns and the need to comply with institutional and ethical guidelines.
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF